Development asset linked to LianBio in public FDA and regional records.
pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
LianBio drug portfolio — 40 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
LianBio pipeline
Portfolio lens on 40 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
LianBio drug portfolio — 40 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to LianBio in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
Development asset linked to LianBio in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to LianBio in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in LianBio's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
daridorexant
Nervous system (N05)Nervous system (N05) compound in LianBio's portfolio. Molecular target: Orexin receptor.
- Target
- Orexin receptor
- Mechanism
- Orexin receptor antagonist
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase 8 inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase-1 inhibitor
-
Development asset linked to LianBio in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to LianBio in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
Development asset linked to LianBio in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.
-
Development asset linked to LianBio in public FDA and regional records.